Advanced Oncotherapy (AVO) – Executive Chairman buys 200,000 shares

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that, yesterday, Dr Mike Sinclair purchased 200,000 Ordinary Shares of 25 pence in the Company at an average price of 30.44 pence per Ordinary Share. Following this transaction, Dr Sinclair now holds 4,928,229 Ordinary Shares, representing 6.65% of the issued […]